行情

REXN

REXN

REXAHN PHARMA
NASDAQ

实时行情|Nasdaq Last Sale

1.960
+0.240
+13.95%
已收盘, 19:28 11/20 EST
开盘
1.650
昨收
1.720
最高
2.020
最低
1.560
成交量
21.86万
成交额
--
52周最高
19.80
52周最低
1.560
市值
787.75万
市盈率(TTM)
-0.7135
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

REXN 新闻

  • 沪指低开震荡 美联储称无意调整利率路径
  • 新浪财经.38分钟前
  • 特朗普催促美国实行负利率 美联储官员不乐意
  • 中国新闻网.2小时前
  • 苹果、英特尔就专利实践对软银子公司发起反垄断诉讼
  • 新浪美股.2小时前
  • 外媒:波音737MAX获大订单 但算不上扭转局面
  • 参考消息.3小时前

更多

所属板块

生物技术和医学研究
+0.65%
制药与医学研究
-0.14%

热门股票

名称
价格
涨跌幅

REXN 简况

Rexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company's clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance. RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including pancreatic, bladder, colon and lung cancer. Supinoxin is a small molecule inhibitor of phosphorylation of p68. The Company also has a drug candidate RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, in pre-clinical development. The Company is working on research technologies, including multi-target aimed ligands platform and nano-based drug delivery systems.
展开

Webull提供Rexahn Pharmaceuticals, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。